Eagle Pharmaceuticals Inc expected to post earnings of 94  cents a share - Earnings Preview

Eagle Pharmaceuticals

25/02/2022 15:09

* Eagle Pharmaceuticals Inc  EGRX.OQ   EGRX.O  is expected
to show
a rise in quarterly revenue when it reports  results on March
7. 
    * The Woodcliff Lake New Jersey-based  company is expected
to
report  a 2.3% increase in revenue to $51.081 million from
$49.92 million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Eagle
Pharmaceuticals Inc
is for earnings of 94 cents per share. For the same quarter last
year, the company reported earnings of 96 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $50.5​, about 5.7% above​ its last
closing price of $47.61. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  0.83        0.83       0.56      Missed  -32.8
 Jun. 30 2021  0.75        0.80       0.93      Beat    16.3
 Mar. 31 2021  0.74        0.65       0.24      Missed  -63.1​
 Dec. 31 2020  -0.20       -0.17      0.96      Beat    656.5
 ​​Sep.        0.33        0.30       1.17      Beat    296.6
 30 2020                                                
 Jun. 30 2020  0.26        0.24       0.57      Beat    142.6​
 Mar. 31 2020  0.58        0.57       0.84      Beat    48
 Dec. 31 2019  0.50        0.47       0.48      Beat    3.2
 This summary was machine generated February 25 at 15:09 GMT. 
All figures in US dollars  unless otherwise stated